Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ponesimod
Therapeutic Area : Neurology
Study Phase : Approved
Recipient : Actelion Pharmaceuticals Ltd
Deal Size : Undisclosed
Deal Type : Acquisition
Juvisé Pharmaceuticals Acquires Ponvory® Ex-US/Canada and Opens Capital To Bpifrance
Details : Juvise Pharmaceuticals will leverage its expertise to commercialize Ponvory (ponesimod), a first-line treatment option for active forms of relapsing multiple sclerosis outside of North America.
Brand Name : Ponvory
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 26, 2024
Lead Product(s) : Ponesimod
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : Actelion Pharmaceuticals Ltd
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Bismuth Potassium Citrate,Metronidazole,Tetracycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Pylera®, a 3-in-1 combination of antimicrobial products, is indicated for the treatment of patients with Helicobacter pylori infection suffering from gastro-duodenal ulcer disease.
Brand Name : Pylera
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 05, 2022
Lead Product(s) : Bismuth Potassium Citrate,Metronidazole,Tetracycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Anastrozole
Therapeutic Area : Oncology
Study Phase : Approved
Recipient : AstraZeneca
Deal Size : Undisclosed
Deal Type : Acquisition
Juvise Pharmaceuticals Successfully Syndicated Its EUR 213 Million Financing in Less than One Month
Details : Arimidex® (anastrozole) and Casodex® (bicalutamide) are hormone treatments for breast and prostate cancer. The two products are recognized as pillar in those cancer treatments and essential for both patients and physicians.
Brand Name : Arimidex
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 04, 2020
Lead Product(s) : Anastrozole
Therapeutic Area : Oncology
Highest Development Status : Approved
Recipient : AstraZeneca
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?